Sam Ghilardi 5/26/26 Sam Ghilardi 5/26/26

Watertown's First Potential IPO since 2023, Remix's Positive Clinical Trial Results, and Triveni Jumps into the Eczema Market

Plus the initial dosing of Enanta and Avencell's Clinical Trials

Sam Ghilardi 5/12/26 Sam Ghilardi 5/12/26

Kestrel's $1.45 billion AbbVie Deal, FDA Approves First Ever PROTAC, and Werewolf Breaks Arsenal Lease.

Plus more details on Windgap's big pharma partnership and a number of people moves.

Sam Ghilardi 3/31/26 Sam Ghilardi 3/31/26

Plus Addgenes' new partnership, and Neumora and Acrivon's cash flow updates

Sam Ghilardi 12/2/25 Sam Ghilardi 12/2/25

Stratus Therapeutics winding down, Consider the ALS TDI for Giving Tuesday, and more

Sam Ghilardi 11/4/25 Sam Ghilardi 11/4/25

Soufflé Therapeutics Launches from Stealth, Disc and Werewolf receive FDA priority, Affini-T may be winding down.